Clinical Trial

A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes. Participants will receive either oral semaglutide D (the treatment being tested) or oral semaglutide (the comparator); which treatment a participant gets is decided by chance. Oral semaglutide is an approved tablet (a treatment used as a comparator), while oral semaglutide D is described as the new tablet formulation being tested in this study. The study will last approximately 27 weeks.
Protocol Amendment History 2 changes
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-04-01
notable Primary completion moved earlier: 2026-08-21 -> 2026-06-29 2026-04-01
Trial Details
NCT Number NCT07271251
Lead Sponsor Novo Nordisk A/S
Conditions Type 2 Diabetes
Enrollment 264 participants
Start Date 2025-12-01
Primary Completion 2026-06-29 (estimated)
Study Completion 2026-08-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-31